Table S1.
Effect of induction regimens for transplant-eligible patients with NDMM on ORR
| Cy-Dex | 1.4 (0.56–3.4) |
3.8 (2.1–6.8) |
3.1 (1.3–7.9) |
2.3 (1.3–4.4) |
3.3 (1.7–6.7) |
1.3 (0.78–2.2) |
6.1 (3.0–12.0) |
3.3 (1.8–6.2) |
4.8 (2.4–9.5) |
9.6 (3.0–31.0) |
6.7 (2.3–19.0) |
11 (5.5–22.0) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.72 (0.29–1.8) |
Dex | 2.7 (1.2–6.1) |
2.3 (1.0–5.2) |
1.7 (0.74–3.9) |
2.4 (1.4–4.3) |
0.94 (0.45–2.0) |
4.4 (2–9.7) |
2.4 (1.1–5.2) |
3.4 (1.4–8.3) |
6.9 (1.9–25.0) |
4.8 (1.5–16.0) |
8.0 (3.8–17.0) |
| 0.26 (0.15–0.47) |
0.36 (0.16–0.81) |
PAD | 0.83 (0.37–1.9) |
0.62 (0.38–0.98) |
0.88 (0.50–1.5) |
0.34 (0.26–0.46) |
1.6 (0.92–2.8) |
0.87 (0.54–1.4) |
1.3 (0.84–1.9) |
2.5 (0.93–1.0) |
1.8 (0.72–4.4) |
2.9 (1.7–4.9) |
| 0.32 (0.13–0.80) |
0.44 (0.19–1.0) |
1.2 (0.53–2.7) |
RD | 0.74 (0.32–1.7) |
1.1 (0.58–1.9) |
0.41 (0.19–0.89) |
1.9 (0.86–4.3) |
1.1 (0.48–2.3) |
1.5 (0.62–3.7) |
3.1 (0.85–11.0) |
2.1 (0.64–7.1) |
3.5 (1.6–7.5) |
| 0.43 (0.23–0.79) |
0.59 (0.26–1.4) |
1.6 (1.0–2.6) |
1.3 (0.58–3.2) |
TAD | 1.4 (0.78–2.6) |
0.56 (0.39–0.80) |
2.6 (1.4–4.7) |
1.4 (0.84–2.4) |
2.0 (1.1–3.7) |
4.1 (1.4–13.0) |
2.8 (1.0–7.9) |
4.7 (2.6–8.4) |
| 0.30 (0.15–0.60) |
0.41 (0.24–0.73) |
1.1 (0.65–2.0) |
0.94 (0.52–1.7) |
0.70 (0.39–1.3) |
TD | 0.39 (0.24–0.63) |
1.8 (1.1–3.1) |
0.99 (0.59–1.7) |
1.4 (0.73–2.8) |
2.9 (0.91–9.2) |
2.0 (0.70–5.7) |
3.3 (2.0–5.3) |
| 0.77 (0.46–1.3) |
1.1 (0.50–2.2) |
2.9 (2.2–3.9) |
2.4 (1.1–5.2) |
1.8 (1.3–2.6) |
2.6 (1.6–4.2) |
VAD | 4.7 (2.9–7.5) |
2.5 (1.7–3.7) |
3.6 (2.2–5.9) |
7.4 (2.6–21.0) |
5.1 (2.0–13.0) |
8.4 (5.3–13.0) |
| 0.16 (0.081–0.33) |
0.23 (0.10–0.50) |
0.62 (0.36–1.1) |
0.52 (0.23–1.2) |
0.39 (0.21–0.70) |
0.55 (0.32–0.95) |
0.21 (0.13–0.35) |
VBMCP-VBAD-B | 0.54 (0.38–0.78) |
0.78 (0.40–1.5) |
1.6 (0.51–5.0) |
1.1 (0.39–3.1) |
1.8 (1.3–2.5) |
| 0.30 (0.16–0.57) |
0.42 (0.19–0.90) |
1.1 (0.71–1.8) |
0.95 (0.43–2.1) |
0.71 (0.42–1.2) |
1.0 (0.60–1.7) |
0.39 (0.27–0.58) |
1.8 (1.3–2.6) |
VD | 1.4 (0.79–2.6) |
2.9 (0.96–8.8) |
2.0 (0.74–5.5) |
3.3 (2.3–4.8) |
| 0.21 (0.10–0.42) |
0.29 (0.12–0.70) |
0.80 (0.54–1.2) |
0.66 (0.27–1.6) |
0.49 (0.27–0.90) |
0.70 (0.36–1.4) |
0.27 (0.17–0.45) |
1.3 (0.66–2.5) |
0.70 (0.38–1.3) |
VDC | 2.0 (0.80–5.2) |
1.4 (0.63–3.2) |
2.3 (1.2–4.4) |
| 0.10 (0.032–0.33) |
0.14 (0.039–0.52) |
0.40 (0.14–1.1) |
0.33 (0.089–1.2) |
0.24 (0.080–0.74) |
0.35 (0.11–1.1) |
0.14 (0.047–0.38) |
0.63 (0.20–2.0) |
0.34 (0.11–1.0) |
0.50 (0.19–1.3) |
VDCR | 0.69 (0.48–0.99) |
1.1 (0.37–3.5) |
| 0.15 (0.051–0.43) |
0.21 (0.062–0.68) |
0.57 (0.23–1.4) |
0.47 (0.14–1.6) |
0.35 (0.13–0.96) |
0.50 (0.17–1.4) |
0.20 (0.076–0.50) |
0.91 (0.32–2.6) |
0.50 (0.18–1.4) |
0.71 (0.32–1.6) |
1.4 (1.0–2.1) |
VDR | 1.7 (0.59–4.6) |
| 0.091 (0.046–0.18) |
0.13 (0.060–0.27) |
0.34 (0.20–0.59) |
0.29 (0.13–0.61) |
0.21 (0.12–0.38) |
0.30 (0.19–0.49) |
0.12 (0.075–0.19) |
0.55 (0.39–0.77) |
0.30 (0.21–0.43) |
0.43 (0.23–0.82) |
0.87 (0.28–2.7) |
0.61 (0.22–1.7) |
VTD |
Note: Data presented as OR (95% CI).
Abbreviations: Cy-Dex, cyclophosphamide plus dexamethasone; Dex, dexamethasone; NDMM, newly diagnosed multiple myeloma; ORR, overall response rate; PAD, bortezomib plus doxorubicin plus dexamethasone; RD, lenalidomide plus dexamethasone; TAD, thalidomide plus doxorubicin plus dexamethasone; TD, thalidomide plus dexamethasone; VAD, vincristine plus doxorubicin plus dexamethasone; VBMCP-VBAD-B, BCNU plus vincristine plus melphalan plus prednisone plus dexamethasone plus bortezomib; VD, bortezomib plus dexamethasone; VDC, bortezomib plus dexamethasone plus cyclophosphamide; VDCR, bortezomib plus dexamethasone plus cyclophosphamide plus lenalidomide; VDR, bortezomib plus dexamethasone plus lenalidomide; VTD, bortezomib plus thalidomide plus dexamethasone